Bibliography
- Lindsay MA. Target discovery. Nat Rev Drug Discov 2003;2(10):831-8
- Ruffolo R. Why has R&D productivity declined in the pharmaceutical industry? Expert Opin Drug Discov 2006;1(2):99-102
- Emilsson V, Thorleifsson G, Zhang B, et al. Genetics of gene expression and its effect on disease. Nature 2008;452(7186):423-8
- Agarwal P, Searls DB. Literature mining in support of drug discovery. Brief Bioinform 2008;9(6):479-92
- Chen YP, Chen F. Identifying targets for drug discovery using bioinformatics. Expert Opin Ther Targets 2008;12(4):383-9
- Cho CR, Labow M, Reinhardt M, et al. The application of systems biology to drug discovery. Curr Opin Chem Biol 2006;10(4):294-302
- Loging W, Harland L, Williams-Jones B. High-throughput electronic biology: mining information for drug discovery. Nat Rev Drug Discov 2007;6(3):220-30
- Yang Y, Adelstein SJ, Kassis AI. Target discovery from data mining approaches. Drug Discov Today 2009;14(3-4):147-54
- Betz UA. How many genomics targets can a portfolio afford? Drug Discov Today 2005;10(15):1057-63
- Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006;5(10):821-34
- Zheng CJ, Han LY, Yap CW, et al. Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol Rev 2006;58(2):259-79
- Drews J. Genomic sciences and the medicine of tomorrow. Nat Biotechnol 1996;14(11):1516-8
- Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1(9):727-30
- Li P, Callery PS, Gan LS, Balani SK. Esterase inhibition by grapefruit juice flavonoids leading to a new drug interaction. Drug Metab Dispos 2007;35(7):1203-8
- Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5(2):100-7
- Stanton BZ, Peng LF, Maloof N, et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat Chem Biol 2009;5(3):154-6
- Imming P, Buss T, Dailey LA, et al. A classification of drug substances according to their mechanism of action. Pharmazie 2004;59(8):579-89
- Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993-6
- Russ AP, Lampel S. The druggable genome: an update. Drug Discov Today 2005;10(23-24):1607-10
- Stockman A, Sharpe LT, Tufail A, et al. The effect of sildenafil citrate (Viagra) on visual sensitivity. J Vis 2007;7(8):1-15
- Bakheet TM, Doig AJ. Properties and identification of human protein drug targets. Bioinformatics 2009;25(4):451-7
- Li Q, Lai L. Prediction of potential drug targets based on simple sequence properties. BMC Bioinformatics 2007;8:353
- Plewczynski D, Rychlewski L. Meta-basic estimates the size of druggable human genome. J Mol Model 2009;15(6):695-9
- Swindells MB, Overington JP. Prioritizing the proteome: identifying pharmaceutically relevant targets. Drug Discov Today 2002;7(9):516-21
- Al-Lazikani B, Gaulton A, Paolini G, et al. The Molecular Basis of Predicting Druggability. In: Lengauer T, editor, Bioinformatics: from Genomes to Therapies. Weinheim: Wiley-VCH 2007. p. 1315-34
- Coleman RG, Salzberg AC, Cheng AC. Structure-based identification of small molecule binding sites using a free energy model. J Chem Inf Model 2006;46(6):2631-7
- Gao Z, Li H, Zhang H, et al. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics 2008;9:104
- Li YY, An J, Jones SJ. A large-scale computational approach to drug repositioning. Genome Inform 2006;17(2):239-47
- Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4(11):682-90
- Sakharkar MK, Sakharkar KR, Pervaiz S. Druggability of human disease genes. Int J Biochem Cell Biol 2007;39(6):1156-64
- Romero P, Wagg J, Green ML, et al. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol 2005;6(1):R2
- Mi H, Lazareva-Ulitsky B, Loo R, et al. The PANTHER database of protein families, subfamilies, functions and pathways. Nucleic Acids Res 2005;33(Database issue):D284-8
- Chang A, Scheer M, Grote A, et al. BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009. Nucleic Acids Res 2009;37(Database issue):D588-92
- Available from: http://www.chem.qmul.ac.uk/iubmb/enzyme/ [Last Accessed March 2009]
- Degtyarenko K, de Matos P, Ennis M, et al. ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res 2008;36(Database issue):D344-50
- Kuhn M, von Mering C, Campillos M, et al. STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res 2008;36(Database issue):D684-8
- Okuda S, Yamada T, Hamajima M, et al. KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res 2008;36(Web Server issue):W423-6
- Sayers EW, Barrett T, Benson DA, et al. Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2009;37 (Database issue):D5-15
- Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009;37(Database issue):D603-10
- Ji HF, Kong DX, Shen L, et al. Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery. Genome Biol 2007;8(8):R176
- Aguero F, Al-Lazikani B, Aslett M, et al. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov 2008;7(11):900-7
- Villate O, Rastrojo A, Lopez-Diez R, et al. Differential splicing, disease and drug targets. Infect Disord Drug Targets 2008;8(4):241-51
- Censarek P, Freidel K, Hohlfeld T, et al. Human cyclooxygenase-1b is not the elusive target of acetaminophen. Eur J Pharmacol 2006;551(1-3):50-3
- Kis B, Snipes JA, Busija DW. Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005;315(1):1-7
- Simmons DL, Chandrasekharan NV, Hu D, et al. Comments on acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties”. J Pharmacol Exp Ther 2005;315(3):1412-4
- Chabre M, Deterre P, Antonny B. The apparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol Sci 2009;30(4):182-7
- Gurevich VV, Gurevich EV. How and why do GPCRs dimerize? Trends Pharmacol Sci 2008;29(5):234-40
- Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450(7172):1001-9
- Stumpf MP, Thorne T, de Silva E, et al. Estimating the size of the human interactome. Proc Natl Acad Sci USA 2008;105(19):6959-64
- Fuller JC, Burgoyne NJ, Jackson RM. Predicting druggable binding sites at the protein-protein interface. Drug Discov Today 2009;14(3-4):155-61
- Alvarez-Salas LM. Nucleic acids as therapeutic agents. Curr Top Med Chem 2008;8(15):1379-404
- Davies MN, Flower DR. Harnessing bioinformatics to discover new vaccines. Drug Discov Today 2007;12(9-10):389-95
- Myler PJ. Searching the Tritryp genomes for drug targets. Adv Exp Med Biol 2008;625:133-40
- Miller JR, Dunham S, Mochalkin I, et al. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc Natl Acad Sci USA 2009;106(6):1737-42
- Holler T, Evdokimov A, Narasimhan L. Structural biology approaches to antibacterial drug discovery. Expert Opin Drug Discov 2007;2(8):1085-101
- Rouquier S, Giorgi D. Olfactory receptor gene repertoires in mammals. Mutat Res 2007;616(1-2):95-102
- De la Cruz O, Blekhman R, Zhang X, et al. A signature of evolutionary constraint on a subset of ectopically expressed olfactory receptor genes. Mol Biol Evol 2009;26(3):491-4
- Hollopeter G, Jantzen HM, Vincent D, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409(6817):202-7
- Greandjean N, Charpiot B, Pena C, Peitsch M. Competitive intelligence and patent analysis in drug discovery: Mining the competitive knowledge bases and patents. Drug Discov Today 2005;2(3):211-5
- Whitby RJ, Dixon S, Maloney PR, et al. Identification of small molecule agonists of the orphan nuclear receptors liver receptor homolog-1 and steroidogenic factor-1. J Med Chem 2006;49(23):6652-5
- Mollica L, De Marchis F, Spitaleri A, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol 2007;14(4):431-41
- Yashiroda Y, Matsuyama A, Yoshida M. New insights into chemical biology from ORFeome libraries. Curr Opin Chem Biol 2008;12(1):55-9
- Andreeva A, Howorth D, Chandonia JM, et al. Data growth and its impact on the SCOP database: new developments. Nucleic Acids Res 2008;36 (Database issue):D419-25
- Hunter S, Apweiler R, Attwood TK, et al. InterPro: the integrative protein signature database. Nucleic Acids Res 2009;37(Database issue):D211-5
- Kundrotas PJ, Alexov E. PROTCOM: searchable database of protein complexes enhanced with domain-domain structures. Nucleic Acids Res 2007;35(Database issue):D575-9
- Luc PV, Tempst P. PINdb: a database of nuclear protein complexes from human and yeast. Bioinformatics 2004;20(9):1413-5
- Mewes HW, Frishman D, Mayer KF, et al. MIPS: analysis and annotation of proteins from whole genomes in 2005. Nucleic Acids Res 2006;34(Database issue):D169-72
- The Minimum Information About a Bioactive Entity (MIABE). Orchard S, 2008. Available from: http://www.psidev.info/index.php?q = node/394 [Last Accessed March 2009]
- Roberts PM, Hayes WS. Information needs and the role of text mining in drug development. Pac Symp Biocomput 2008;592-603
- Billingsley ML. Druggable targets and targeted drugs: enhancing the development of new therapeutics. Pharmacology 2008;82(4):239-44
- Chin G, Stephan E, Gracio D, et al. Developing concept-based user interfaces for scientific computing. Computer 2006;39(9):26-34
- Available from: http://www.i2.co.uk [Last Accessed March 2009]
- Campbell S, Gaulton A, Harland L, et al. Visualising the drug target landscape. Manuscript In Preparation
- Reidhaar-Olson J, Braxenthaler M, Hammer J. Process biology: integrated genomics and bioinformatics tools for improved target assessment. Targets 2002;1(6):189-95
- Schimmer AD. Chemical biology – understanding biology and advancing therapy. Clin Invest Med 2008;31(5):E282-9
- Bajorath J. Computational analysis of ligand relationships within target families. Curr Opin Chem Biol 2008;12(3):352-8
- Gaither LA. Chemogenomics approaches to novel target discovery. Expert Rev Proteomics 2007;4(3):411-9
- Harris CJ, Stevens AP. Chemogenomics: structuring the drug discovery process to gene families. Drug Discov Today 2006;11(19-20):880-8
- Klabunde T. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands. Br J Pharmacol 2007;152(1):5-7
- Roter AH. Large-scale integrated databases supporting drug discovery. Curr Opin Drug Discov Dev 2005;8(3):309-15
- Wuster A, Madan Babu M. Chemogenomics and biotechnology. Trends Biotechnol 2008;26(5):252-8
- Paolini GV, Shapland RH, van Hoorn WP, et al. Global mapping of pharmacological space. Nat Biotechnol 2006;24(7):805-15
- Gregori-Puigjane E, Mestres J. A ligand-based approach to mining the chemogenomic space of drugs. Comb Chem High Throughput Screen 2008;11(8):669-76
- Keiser MJ, Roth BL, Armbruster BN, et al. Relating protein pharmacology by ligand chemistry. Nat Biotechnol 2007;25(2):197-206
- Bernasconi P, Chen M, Galasinski S, et al. A chemogenomic analysis of the human proteome: application to enzyme families. J Biomol Screen 2007;12(7):972-82
- Mestres J, Martin-Couce L, Gregori-Puigjane E, et al. Ligand-based approach to in silico pharmacology: nuclear receptor profiling. J Chem Inf Model 2006;46(6):2725-36
- Fliri AF, Loging WT, Thadeio PF, Volkmann RA. Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci USA 2005;102(2):261-6
- Oprea TI, Tropsha A, Faulon JL, Rintoul MD. Systems chemical biology. Nat Chem Biol 2007;3(8):447-50
- Scheiber J, Chen B, Milik M, et al. Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model 2009;49(2):308-17
- di Bernardo D, Thompson MJ, Gardner TS, et al. Chemogenomic profiling on a genome-wide scale using reverse-engineered gene networks. Nat Biotechnol 2005;23(3):377-83
- Aronson JK. Old drugs – new uses. Br J Clin Pharmacol 2007;64(5):563-5
- Emre N, Coleman R, Ding S. A chemical approach to stem cell biology. Curr Opin Chem Biol 2007;11(3):252-8
- Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448(7154):645-6
- O'Connor KA, Roth BL. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 2005;4(12):1005-14
- Innovative Strategies for Drug Repurposing. Grau D, Serbedzija G, 2005. Available from: http://www.dddmag.com/innovative-strategies-for-drug.aspx [Last Accessed March 2009]
- Wermuth CG. Selective optimization of side activities: another way for drug discovery. J Med Chem 2004;47(6):1303-14
- Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003;100(13):7977-82
- Zimmermann GR, Avery W, Finelli AL, et al. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res Ther 2009;11(1):R12
- Weeber M, Vos R, Klein H, et al. Generating hypotheses by discovering implicit associations in the literature: a case report of a search for new potential therapeutic uses for thalidomide. J Am Med Inform Assoc 2003;10(3):252-9
- Ha S, Seo YJ, Kwon MS, et al. IDMap: facilitating the detection of potential leads with therapeutic targets. Bioinformatics 2008;24(11):1413-5
- Hopkins A, Harland L, Lanfear J, et al. System and method for the computer-assisted identification of drugs and indications US20050060305; 2005
- Evans R, Hinds S, Hammock D. Portfolio analysis and R&D decision making. Nat Rev Drug Discov 2009;8(3):189-90
- Rhodes J, Boyer S, Kreulen J, et al. Mining patents using molecular similarity search. Pac Symp Biocomput 2007;304-15
- Williams C. cAMP detection methods in HTS: selecting the best from the rest. Nat Rev Drug Discov 2004;3(2):125-35
- Dow ER, Hughes JB, Stephens SM, et al. Integrating scientific data for drug discovery and development using the Life Sciences Grid. Expert Opin Drug Discov 2009;4(6):687-699
- Hohman M, Gregory K, Chibale K, et al. Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today 2009;14(5-6):261-70
- Smith B, Ashburner M, Rosse C, et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol 2007;25(11):1251-5
- Overington J. ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). J Comput Aided Mol Des 2009;23(4):195-8
- Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006;34(Database issue):D668-72
- Korstanje C. Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development. Curr Opin Investig Drugs 2003;4(5):519-21
- Parekh RB, Rohlff C. Post-translational modification of proteins and the discovery of new medicine. Curr Opin Biotechnol 1997;8(6):718-23
- Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298(5600):1912-34
- Barnes PJ. Role of HDAC2 in the Pathophysiology of COPD. Annu Rev Physiol 2009;71:451-64
- Durant ST, Cho EC, La Thangue NB. p53 methylation – the Arg-ument is clear. Cell Cycle 2009;8(6):801-2
- Yang XD, Huang B, Li M, et al. Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO J 2009;28(8):1055-66
- Kiemer L, Bendtsen JD, Blom N. NetAcet: prediction of N-terminal acetylation sites. Bioinformatics 2005;21(7):1269-70
- Linding R, Jensen LJ, Pasculescu A, et al. NetworKIN: a resource for exploring cellular phosphorylation networks. Nucleic Acids Res 2008;36 (Database issue):D695-9
- Chen H, Xue Y, Huang N, et al. MeMo: a web tool for prediction of protein methylation modifications. Nucleic Acids Res 2006;34 (Web Server issue):W249-53
- Lee TY, Huang HD, Hung JH, et al. dbPTM: an information repository of protein post-translational modification. Nucleic Acids Res 2006;34 (Database issue):D622-7
- Kang R, Wan J, Arstikaitis P, et al. Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature 2008;456(7224):904-9
- Perez EE, Wang J, Miller JC, et al. Establishment of HIV-1 resistance in CD4 + T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 2008;26(7):808-16
- Aspirin: Not Approvable. Why many familiar medicines might flunk FDA approval today. Lowe D, 2005. Available from: http://www.medicalprogresstoday.com/spotlight/spotlight_indarchive.php?id = 1039; [Last Accessed March 2009]